Overview

Tadalafil is a long-acting phosphodiesterase type 5 (PDE5) inhibitor — the same drug class as sildenafil, distinguished by a long elimination half-life of roughly 17.5 hours. That long half-life is the whole reason a low dose taken once daily can hold steady blood levels around the clock rather than being used only on demand (pharmacology; established).

It is approved by the Food and Drug Administration for three related uses: erectile dysfunction, the lower-urinary-tract symptoms of benign prostatic hyperplasia (an enlarged prostate), and the two together (regulatory; supported by randomized trials).

It is on members' radar for a reason beyond those approved uses. The optimization community has increasingly reframed daily low-dose tadalafil as a general "longevity" or "vascular health" supplement, pointing to observational associations with lower mortality and fewer cardiovascular events. That reframing is exactly where the evidence thins out, and it is the tension this monograph is built around: a drug that is genuinely well-proven for what it was approved to do, wearing a second reputation the data does not yet support.

Evidence

Organized strongest tier first.

Randomized controlled trials (strongest). In the once-daily registration program, tadalafil 2.5 mg and 5 mg significantly improved erectile function versus placebo on the erectile-function domain of the International Index of Erectile Function (P < 0.001) (randomized controlled trial). For the urinary symptoms of an enlarged prostate, a 12-week randomized, placebo-controlled trial in men who had both erectile dysfunction and benign prostatic hyperplasia found that the International Prostate Symptom Score improved by a mean of 6.1 points on 5 mg once daily versus 3.8 points on placebo; the smaller change on 2.5 mg (4.6 points) was not statistically separated from placebo for that endpoint (randomized controlled trial). A separate systematic review and meta-analysis of tadalafil 5 mg once daily reported improvement in both lower-urinary-tract symptoms and erectile function (meta-analysis of randomized trials). The daily-use approval rests on a program of approximately 1,989 men across placebo-controlled studies, with good tolerability over 12 weeks (randomized controlled trials).

The honest summary of this tier: for its two approved jobs, tadalafil has the kind of randomized-trial evidence most supplements never accumulate.

Observational / epidemiological (association only). Large observational analyses published in 2024 and 2025 have associated PDE5-inhibitor use with lower all-cause mortality and lower rates of cardiovascular events. A 2025 analysis reported that tadalafil users had lower rates of all-cause death, myocardial infarction, stroke, venous thromboembolism, and dementia, with reported reductions on the order of roughly 20 to 34 percent across those outcomes (observational cohort). These are associations, not experiments. Men who are prescribed and who fill these drugs differ systematically from men who do not — they tend to be healthier, more sexually active, and more engaged with medical care — and that healthy-user confounding is the default explanation for a mortality signal until a randomized trial says otherwise. The association is real; the causal reading is not earned.

Mechanistic and small-trial findings (biologically interesting). Chronic tadalafil has been reported to improve flow-mediated dilation — a measure of the function of the endothelium, the inner lining of blood vessels — in patients at increased cardiovascular risk (small randomized/mechanistic study). This is a plausible mechanism by which a vascular drug might help the vasculature; it is an intermediate marker, not a demonstration of fewer heart attacks or deaths. A separate small study reported that daily 5 mg for two months increased lean body mass compared with on-demand dosing (small study; hypothesis-generating).

A limiting randomized trial (the counterweight). When PDE5 inhibition was actually put to a prospective randomized test for cognition, a National Institutes of Health–funded trial (DREAM) did not find that it reduced Alzheimer's risk (randomized controlled trial; null result). This is a useful correction to the observational dementia signal above: where a stronger tier and a weaker tier disagree, the stronger tier wins, and here the trial did not confirm the association.

Clinical relevance

Mechanism (labeled as mechanism). PDE5 inhibitors block the enzyme that breaks down cyclic GMP, which sustains nitric-oxide–mediated smooth-muscle relaxation and blood flow. Clinically that plays out in the penis (erections), in the prostate and bladder neck (urinary symptoms), and in vascular endothelium generally. The long half-life is what makes once-daily steady-state dosing practical rather than on-demand.

The single most important safety point is an interaction, not a side effect. Combining any PDE5 inhibitor with nitrates — nitroglycerin, isosorbide, and related drugs common in coronary artery disease — can cause profound, potentially fatal drops in blood pressure. This is an absolute contraindication. Because of tadalafil's long half-life, guidance is to separate it from any nitrate by at least 48 hours. Caution also applies with alpha-blockers (often prescribed for the same prostate symptoms) and other blood-pressure medications, which can compound the effect (drug labeling; pharmacology).

Common adverse effects are usually mild: headache, flushing, nasal congestion, indigestion, and a characteristic back or muscle ache that appears 12 to 24 hours after a dose and typically resolves within about 48 hours (randomized-trial tolerability data and labeling).

Rare but urgent: non-arteritic anterior ischemic optic neuropathy (sudden vision loss), priapism, and sudden hearing loss are recognized class effects that warrant stopping the drug and seeking care immediately (pharmacovigilance).

For You (practical, education only)

Framed as what the evidence would suggest for someone discussing this with their own physician — not a recommendation to take anything.

For erectile dysfunction, or for bothersome urinary symptoms from an enlarged prostate, daily low-dose tadalafil is a well-studied, effective, and generally well-tolerated prescription option, and one of the better-evidenced tools in men's health (randomized-trial tier).

The "take it for longevity" case is a different matter and is not established. The mortality and cardiovascular associations are real data, but they are observational and cannot tell you the drug caused the benefit. Treating that association as if it were proof is precisely the reasoning error this platform exists to flag (observational; caveat).

And because this is a prescription drug with a hard nitrate contraindication, the safe path runs through a clinician who knows your entire medication list — not a telehealth checkout page that never asks (safety framing, not a prescription).

Uncertainty and open questions

Does daily tadalafil actually extend life or prevent cardiovascular events, or are healthier men simply the ones taking it? Only a randomized trial designed for those outcomes could separate those possibilities, and that trial has not been done.

The endothelial-function finding is an intermediate marker. Better flow-mediated dilation has not been shown to translate into fewer real events in this setting.

The dementia association is directly undercut by the null DREAM trial for Alzheimer's risk. Taken together, the cognitive story is, at best, unresolved.

Where the optimization space has outrun the science: a prescription medicine is being marketed and sold online as a daily "longevity supplement," frequently without meaningful medical oversight. The distance between "improves an endothelial marker and is associated with lower mortality" and "will make you live longer" is being quietly erased in that framing. The concrete real-world hazard is not the marketing — it is the man with coronary disease, quietly taking nitrates, who self-sources tadalafil online and tells no one.

References

Claims above trace to the following sources from the current-research pass (grouped by tier):

  • Registration randomized trials (ED and BPH). Once-daily tadalafil 2.5/5 mg improved the IIEF erectile-function domain and IPSS versus placebo in a 12-week randomized, placebo-controlled study (IPSS mean change −6.1 on 5 mg vs −3.8 placebo; 2.5 mg −4.6, not separated from placebo for IPSS); daily-use approval program ~1,989 men (PubMed 21981682). (Randomized controlled trials; FDA approval basis.)
  • Meta-analysis. Systematic review and meta-analysis of tadalafil 5 mg once daily for lower-urinary-tract symptoms and erectile dysfunction (PubMed 29341503). (Meta-analysis of randomized trials.)
  • Observational mortality/cardiovascular/dementia associations. Aging Cell (2024) and The American Journal of Medicine (March 2025) cohort analyses associating PDE5-inhibitor / tadalafil use with lower all-cause mortality (~34%), myocardial infarction (~27%), stroke (~34%), venous thromboembolism (~21%), and dementia (~32%). (Observational.)
  • Endothelial function. Chronic tadalafil and improved flow-mediated dilation in higher-cardiovascular-risk patients (European Urology). (Small randomized/mechanistic.)
  • Lean mass. Daily 5 mg for two months versus on-demand dosing and lean-mass change (Endocrine Connections, 2017). (Small study.)
  • Cognition, prospective. NIH-funded DREAM randomized trial — no reduction in Alzheimer's risk. (Randomized controlled trial; null.)

Disclaimer

This monograph is physician-led educational content. It is not medical advice, and it does not diagnose, treat, or establish a doctor-patient relationship. Tadalafil is a prescription medication, not a supplement; it carries interactions — most importantly with nitrates — and risks specific to your health. Talk with your own physician before making any changes.